Cargando…
Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-α and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression
We previously reported the beneficial effects of combination therapy of interferon (IFN)-α/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumour thrombi in the major portal branches. This report describes the results of longer follow-up and includes more than double the number...
Autores principales: | Ota, H, Nagano, H, Sakon, M, Eguchi, H, Kondo, M, Yamamoto, T, Nakamura, M, Damdinsuren, B, Wada, H, Marubashi, S, Miyamoto, A, Dono, K, Umeshita, K, Nakamori, S, Wakasa, K, Monden, M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361594/ https://www.ncbi.nlm.nih.gov/pubmed/16106266 http://dx.doi.org/10.1038/sj.bjc.6602742 |
Ejemplares similares
-
Activation of Wnt/β-catenin signalling pathway induces chemoresistance to interferon-α/5-fluorouracil combination therapy for hepatocellular carcinoma
por: Noda, T, et al.
Publicado: (2009) -
MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells
por: Tomimaru, Y, et al.
Publicado: (2010) -
Insulin-like growth factor-binding protein 7 alters the sensitivity to interferon-based anticancer therapy in hepatocellular carcinoma cells
por: Tomimaru, Y, et al.
Publicado: (2010) -
Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells
por: Wada, Hiroshi, et al.
Publicado: (2009) -
The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma
por: Ito, Y, et al.
Publicado: (2000)